We therefore propose that EMP1 upregulation represents a critical driver of HSC activation and inflammatory liver injury during MASLD-IRI, although the underlying molecular mechanisms require further elucidation. The gene discussed is EMP1; the disease is metabolic dysfunction-associated steatotic liver disease.